Abstract
BackgroundThe high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Despite the current information on the risk-benefit balance of these drugs, their consumption remains particularly high. We determined the trend in the consumption prevalence of benzodiazepines (BZDs) and drugs related to BZDs (Z-drugs) in the population of the Health Region of Lleida to explore patterns of use and the associated characteristics associated between 2002 and 2015.MethodsAn analysis of secular trends was carried out between 2002 and 2015; the databased included all individuals from the Health Region of Lleida, which had 358,157 inhabitants in 2015, that consumed BZDs. The consumption of BZDs was evaluated using prescription billing data from the Public Health System. All types of BZDs and BZD analogues that had been approved by the drug agency were included. Trends by age and sex were investigated.ResultsOver the whole study period, a total of 161,125 individuals accounted for 338,148 dispensations. Overall, 59% were women, and the mean age was 56 years. The dispensing prevalence of BZDs use in 2015 was 14.2% overall —18.8% in women and 9.6% in men—and was 36% in those over 65 years. According to the half-life of BZDs, the prevalence of short-intermediate BZD use, intermediate-long BZD use, and Z-drugs use was 9.7, 5.5 and 0.8%, respectively. The evolution of the annual prevalence of BZD dispensing showed a progressive decline, from 15.3% in 2002 to 14.2% in 2015, which was attributed to a decrease in the consumption of intermediate-long half-life BZDs (8.0% vs. 5.5%) and Z-drugs (1.4% vs. 0.8%).ConclusionThe dispensing prevalence of BZDs and Z-drugs was high, although a small reduction was observed during this time period. The dispensing prevalence was especially high in the population over 65, despite the risk of cognitive decline and falls. Integral actions are required to lower the BZD prescription rate.
Highlights
The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients
The database consisted of all individuals of any age and sex who were assigned, either by a doctor or by the Basic Health Area, to the Health Region of Lleida (Catalonia), with had a catchment area of 358, 157 inhabitants in 2015
During the period 2002–2015, the cohort of BZD and/or Drugs related to benzodiazepines (Z-drugs) consumers during the period 2002–2015 in the Health Region of Lleida consisted of 161,125 subjects
Summary
The high prevalence and long-term use of benzodiazepines (BZDs) treatment are debated topics because of the risk they can cause to the patients. Benzodiazepines (BZDs) and drugs related to benzodiazepines (Z-drugs) are one of the most highly used pharmacological groups globally, especially in developed countries [1, 2] Their consumption has reached 30% for people over 65 years of age in France [3], more than 20% in Canada [4] and Spain [5], 15% in Australia [6], and between 9 and 12% in the US [7, 8]. A maximum duration of between 2 and 4 weeks for insomnia or anxiety and no more than 2 weeks for mixed anxiety-depressive disorders are advised [11] These recommendations were based on the longterm development of tolerance, dependence, abuse and withdrawal syndrome [12], recent retrospective studies showed a level of dependence after chronic consumption that was lower than previously described, even in older people [13]. BZDs have been demonstrated to increase the risk of falls, hip fractures and detrimental cognitive effects [14, 15]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
